43rd Annual J.P. Morgan Healthcare Conference 2025
Logotype for Ambu

Ambu (AMBU) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Event summary combining transcript, slides, and related documents.

Logotype for Ambu

43rd Annual J.P. Morgan Healthcare Conference 2025 summary

10 Jan, 2026

Business performance and market overview

  • Achieved close to 20% growth in endoscopy solutions and completed a business turnaround, positioning for further market leadership in single-use endoscopy.

  • Single-use endoscopes accounted for two-thirds of all such procedures globally in 2024, with 2.4 million procedures performed.

  • The addressable market is about 100 million annual procedures, with less than 4% currently using single-use devices; current portfolio serves 23 million procedures.

  • Endoscopy solutions now represent 60% of total revenue, with North America contributing about half of overall revenue.

  • Five-year revenue CAGR stands at 14%, with endoscopy solutions growing at 28% CAGR, more than tripling revenue in that segment.

Strategic initiatives and operational improvements

  • The "Zoom In" strategy, launched two years ago, focused on targeted growth, execution, and sustainability, delivering significant EBIT margin improvement of over nine percentage points.

  • All single-use endoscopes converted to bioplastic within 12 months, with ongoing sustainability initiatives and SBTi-validated emission targets.

  • Achieved positive free cash flow and became debt-free, enabling greater investment in growth.

  • Transformation program brought new management capabilities and operational model updates, supporting scalable growth.

Segment performance and innovation

  • Pulmonology returned to double-digit growth (11.7%) after post-COVID turbulence; other segments (urology, ENT, GI) grew nearly 30%.

  • Maintains leadership in single-use endoscopy across all four segments, with highest penetration in pulmonology and growing presence in urology, ENT, and GI.

  • Workflow efficiency, cost savings, and sustainability are key drivers for adoption, with single-use endoscopes offering lower CO2 footprint than reusables.

  • New product launches include a video laryngoscope for pulmonology and high-definition cystoscope and ureteroscope for urology, all integrated on a single software platform.

  • AI and software advancements are expected to further enhance image quality and reduce costs, supporting future growth.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more